WESTFORD, Mass., March 15, 2011 /PRNewswire/ -- Cynosure, Inc.
(Nasdaq: CYNO), a leader in laser- and light-based treatments for
minimally invasive and non-invasive aesthetic applications, today
announced that two of its newest workstations for laser-assisted
lipolysis and non-invasive cellulite reduction have received key
international regulatory clearances.
Health Canada has issued a
Medical Device License authorizing the sale in Canada of the company's SmoothShapes® XV
system for the temporary reduction in the appearance of cellulite.
The non-invasive SmoothShapes XV treats cellulite through a
proprietary process known as Photomology®, which combines laser and
light energy with mechanical manipulation (vacuum and massage) to
produce tighter, smoother-looking skin.
Overseas, the Korea Food and Drug Administration has granted
marketing approval to Cynosure's Smartlipo Triplex™, the company's
minimally invasive technology for fat removal and skin tightening.
The system uses Cynosure's patented MultiPlex technology to combine
three wavelengths – 1064 nm, 1320 nm and 1440 nm – in one laser
output. MultiPlex technology enables multiple wavelengths to
be fired sequentially, creating a blended thermal and
photomechanical effect that efficiently liquefies fat and tightens
skin through tissue coagulation.
Cynosure plans to sell the products through its direct sales
force in North America and
Korea.
SmoothShapes XV and Smartlipo Triplex are also cleared for
marketing in the United States by
the U.S. Food and Drug Administration. Additionally, SmoothShapes
XV is CE marked for sale in the European Union.
"SmoothShapes XV and Smartlipo Triplex are treatments that we
believe deliver a superior outcome for the high-volume aesthetic
applications they serve," said Michael
Davin, president and chief executive officer of Cynosure.
"The Cynosure brand is well established in Canada and Korea, and these clearances
represent incremental growth opportunities. We are delighted
to bring two of our newest workstations to these attractive
markets."
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems
that are used by physicians and other practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and pigmented lesions, rejuvenate the skin, liquefy
and remove unwanted fat through laser lipolysis and reduce the
appearance of cellulite. Cynosure's products include a broad
range of laser and other light-based energy sources, including
Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense
pulsed light. Cynosure was founded in 1991. For corporate or
product information, contact Cynosure at 800-886-2966, or visit
www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Cynosure, Inc., as well as other statements
containing the words "believes," "anticipates," "plans," "expects,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the global economy and lending
environment and their effects on the aesthetic laser industry,
Cynosure's history of operating losses, its reliance on sole source
suppliers, the inability to accurately predict the timing or
outcome of regulatory decisions, changes in consumer preferences,
competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which
are filed with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent Cynosure's views as of the date of this press
release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, while
Cynosure may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be
relied upon as representing Cynosure's views as of any date
subsequent to the date of this press release.
Contact:
|
|
|
|
Scott Solomon
|
|
Vice President
|
|
Sharon Merrill Associates,
Inc.
|
|
Phone: (617) 542-5300
|
|
cyno@investorrelations.com
|
|
|
|
|
SOURCE Cynosure, Inc.